For the month ended 31 August 2026, Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital, underscoring a steady equity base throughout the period.
Authorised Capital • Total authorised share capital remained unchanged at RMB 198.89 million, comprising 197.67 million H-shares and 1.22 million unlisted ordinary shares, each with a par value of RMB 1.00.
Issued Shares • Issued H-shares stood at 197.67 million, with no treasury shares outstanding. • Issued unlisted ordinary shares held flat at 1.22 million. • No new shares were issued, cancelled, or repurchased during the month.
Public Float Status • The company confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public-float threshold for H-shares as at 31 August 2026.
Equity Incentive Capacity • An H-Share Award Scheme—approved on 17 December 2025—still allows for up to 9.94 million shares to be granted. No shares were issued under the scheme during the reporting month.
Overall, Leads Biolabs maintained a stable share structure in August, with regulatory float requirements met and existing headroom available for future equity incentives.
Comments